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Background: The resurgence of multi-drug resistant tuberculosis (MDR-TB) and HIV associated tuberculosis (TB) are
of serious global concern. To contain this situation, new anti-tuberculosis drugs and reduced treatment regimens
are imperative. Recently, a nitroimidazole, PA-824, has been shown to be active against both replicating and non-
replicating bacteria. It is activated by the enzyme Deazaflavin-dependent nitroreductase (Ddn) present in
Mycobacterium tuberculosis which catalyzes the reduction of PA-824, resulting in the release of lethal reactive
nitrogen species (RNS) within the bacteria. In this context, PA-824 was analyzed for its activity against latent
tuberculosis under anaerobic conditions and compared with rifampicin (RIF) and pyrazinamide (PZA). Recent
mutagenesis studies have identified A76E mutation which affects the above mentioned catalysis and leads to PA-
824 resistance. Hence, novel analogues which could cope up with their binding to mutant Ddn receptor were also
identified through this study.
Results: PA-824 at an optimum concentration of 12.5 μg/ml showed enhanced bactericidal activity, resulting in
0 CFU/ml growth when compared to RIF and PZA at normal pH and anaerobic condition. Further docking studies
revealed that a combinatorial structure of PA-824 conjugated with moxifloxacin (ligand 8) has the highest binding
affinity with the wild type and mutant Ddn receptor.
Conclusions: PA-824 has been demonstrated to have better activity under anaerobic condition at 12.5 μg/ml,
indicating an optimized dose that is required for overcoming the detoxifying mechanisms of M. tuberculosis and
inducing its death. Further, the development of resistance through A76E mutation could be overcome through the
in silico evolved ligand 8.
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It is estimated that one-third of the world’s population is
infected with M. tuberculosis and 8.7 million suffer from
active TB and 1.4 million deaths occur due to it every
year [1]. M. tuberculosis is able to evade the human
immune response in part by triggering formation of in-
sulating hypoxic granulomas following infection of pul-
monary macrophages. Bacilli within this environment* Correspondence: cn.paramasivan@finddiagnostics.org
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distribution, and reproduction in any mediumhave adapted themselves to slowly replicate and respire,
making them tolerant of many drugs. This resistant state
is thought to contribute to the prolonged combination
chemotherapy required to cure patients [2,3]. Lack of
compliance with treatments lasting up to 9 months
contributes to the emergence of resistant strains [4]. To
contain this situation, new anti-tuberculosis drugs and
lesser duration of treatment are of immediate require-
ment. The discovery of new drugs involves several con-
straints that discourage many companies from investing
in novel anti-TB drugs. The research is expensive, slow
and difficult, and it requires specialized facilities forCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in designing novel drugs to tackle intractable TB has be-
come feasible [5]. PA-824 is a nitroimidazole, a class of
novel anti-bacterial agents. As a potential TB therapy, it
has many attractive characteristics including, its novel
mechanism of action, its in vitro activity against all
tested drug-resistant clinical isolates, and its activity
both as a potent bactericidal and sterilizing agent in
mice. In addition, the compound shows no evidence
of mutagenicity in a standard battery of genotoxicity
studies, no significant cytochrome P450 interactions,
and no significant activity against a broad range of
Gram-positive and Gram-negative bacteria [6]. Murine
model and a pre clinical study showed a substantial
activity on persisters [7,8]. These reasons necessitate us
to characterize the in vitro activity of PA-824 under
anaerobic conditions, a home for persisters. Further, an
in silico derivative of PA-824 is proposed that could act
under a key resistance mutation (A76E), attributed to
cause PA-824 resistance in M. tuberculosis [9].
Methods
Drugs
PA-824 was provided by the Global Alliance for Tuber-
culosis Drug Development through Doris Rouse of Re-
search Triangle Institute (Research Triangle Park, NC).
PA-824 was prepared in Dimethyl Sulfoxide (DMSO);
Pyrazinamide (PZA) (Sigma) in sterile distilled water
and Rifampicin (RIF) (Sigma) in dimethyl formamide
(DMF). They were sterilized by filtration through cellu-
lose membranes with a pore size of 0.22 μm, and further
dilutions were then made in sterile distilled water.
In vitro oxygen depletion assay for M. tuberculosis
The protocol used for the M. tuberculosis - in vitro
oxygen depletion assay was a slight modification of
the method described by Wayne and Hayes [10] and
Wayne’s Nonreplicating Persistence-2 (NRP-2) model
[11]. Briefly, mid-log-phase aerobic M. tuberculosis
H37Rv cultures were prepared in 10 ml of 7H9 liquid
medium with Tween 80-albumin-dextrose by inoculating
M. tuberculosis H37Rv and incubating at 37°C for 5–
7 days and the number of organisms were counted by
using Thoma counter (Neubauer). Known volume (106
organisms/ml) was inoculated into 18.6 ml of DubosTable 1 Bacterial count in Log10 cfu/ml with standard deviati
Days 0 2 4
No drug 6.55 ± 0.16 6.68 ± 0.23 6.58 ± 0.13
P1 (3 μg/ml) 6.64 ± 0.39 6.45 ± 0.08 6.48 ± 0.22
P2 (12.5 μg/ml) 6.67 ± 0.25 5.44 ± 0.44 4.69 ± 0.12
RIF (1 μg/ml) 6.93 ± 0.04 6.54 ± 0.13 6.62 ± 0.05
PZA (50 μg/ml) 6.08 ± 0.39 6.84 ± 0.02 6.83 ± 0.03medium at a normal pH in 28 ml screw-cap McCartney
bottles (universal containers) from Fishers Scientific Co
Ltd., with methylene blue dye (1.5 g/ml) as an indicator
of oxygen depletion. The blue dye fades and finally
disappears under anaerobic conditions, as described by
Wayne and Hayes [10]. Two to three mm diameter
hole was made on the lid with rubber septa, of the con-
tainers and the mouth was sealed with parafilm. The
H37Rv culture was grown at 37°C in an orbital shaker
(Cetromat) at 1000 rotations /min with slow stirring
for 21 days. It was shaken steadily but not very actively,
to keep the bacilli in suspension and to prevent from
clumping. The culture was grown under closed caps
with a limited headspace. After 21 days, O2 in the
headspace was consumed and the bacteria were in a
non-replicating and low metabolic state called NRP 2
stage. Then 0 day (Viable count) VC was set up on
7H11 agar plates and the drugs were added at different
concentrations.
Bactericidal action of the drugs
PA-824 was injected at two different concentrations of
3 μg/ml (P1), 12.5 μg/ml (P2), and RIF & PZA were
injected at 1 μg/ml and 50 μg/ml respectively through
the septa of 21-day-old cultures. Culture bottles were
prepared in duplicates for each concentration of the
drugs. The culture was removed by means of a syringe
through the septa and the VC was set up on 2nd, 4th,
7th, 10th, 14th, and 21st days. The cultures were serially
diluted in saline and plated onto 7H11/OADC agar
(Difco) plates in duplicates containing polymyxin B (200
U/ml), amphotericin B (20 μg/ml), carbenicillin (100 μg/
ml), and trimethoprim (10 μg/ml), to determine colony-
forming unit (CFU) counts. The plates were placed in
polythene bags, along with a plate inoculated with Myco-
bacterium phlei and incubated at 37°C. M. tuberculosis
colonies were counted at 0, 2, 4, 7, 11, 14 and 21 days of
incubation. The results were represented, as the mean of
the quadruplicates of the cultures for every time point
for every drug concentration and for the control cultures
it was the mean of duplicates (Table 1).
Statistics
The results were expressed as the mean of the dupli-
cates at each time point. Differences in the regressionon on different days
7 11 14 21
6.28 ± 0.23 6.35 ± 0.12 6.37 ± 0.09 6.53 ± 0.07
6.21 ± 0.19 6.20 ± 0.17 5.62 ± 0.54 4.93 ± 0.32
4.18 ± 0.41 4.18 ± 0.51 4.15 ± 0.09 0
5.2 ± 0.28 5.35 ± 0.06 4.60 ± 0.4 4.59 ± 0.48
6.30 ± 0.13 6.02 ± 0.44 6.33 ± 0.3 6.49 ± 0.06
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combinations were tested by analysis of variance using
test command in Stata, release 8 (Stata Corp, College
station Tx). The standard deviation (SD) of a result
was obtained from the variation between CFU counts
on the duplicate cultures, estimated separately for the
log phase and the stationary phase cultures.Graphing
No adequate representation on a logarithmic axis of the
CFU count could be made of counts that yielded no col-
onies since log 0 is minus infinity. A line was therefore
drawn to extrapolate the values obtained at the two
previous time points provided that it cut the X axis to
the left of the time point yielding no colonies. Other-
wise, the line was drawn through Log 0. In each case,
the line concerned has been drawn dotted to indicate
the uncertainty in its true position. Counts after the first
negative count always failed to yield colonies, and their
values have not been entered in the graphs.Docking tools
The binding affinity of the analogues were obtained using
AUTODOCK Vina tool with AMBER force field and
Monte Carlo simulated annealing [12]. The dockings were
performed in a 64 bit PC. The receptor design was made
by using SWISS-MODEL, a fully automated protein struc-
ture homology-modeling server. In this tool, energy
minimization and simulated annealing are done with
the GROMOS96 forcefield [13]. The 2D structures
of the ligands were drawn, optimized with full
hydrogen bonds and saved as .sk2 format using
ChemSketch tool from Advanced Chemistry Devel-
opment, Inc. (ACD/ChemSketch, [14]) and the 3D
structures were obtained using PRODRG server [15].Receptors
The wild type receptor was derived from the crystal
structure of deazaflavin dependent nitroreductase
(3R5W) [16]. The mutant receptor was designed by
introducing A76E mutation [9], in the sequence of Ddn
and modeling it using SWISS MODEL without the
presence of its cofactor F420.Ligands
The ligands were derived from the structure of PA-824
by removing the trifluoromethyl group (CF3) and re-
placing it with key anti-M. tuberculosis drugs such as
isoniazid, moxifloxacin, gatifloxacin etc., through ester
linkages. The removal of trifluoromethyl group was done
on the basis to reduce the toxicity [17]. The designed
combinatorial ligands are listed in Table 2.Analysis of binding
The binding sites for the docking were designed
such that the entire receptor molecule was in-
cluded within the selection grid. The highest binding
energy values corresponding to the RMSD value of
zero were considered as the binding affinity value of
the ligands for each docking. The Hydrogen bond
interactions were obtained using Molegro molecular
viewer (molegro.com) [18].Results
Bactericidal activity
The results of the bactericidal activity of different drugs
from the two sets of experiments are given in Figure 1.
PA-824 at lower concentration of 3 μg/ml (P1) had less
activity on all the days resulting with a log of 4.9 CFU/
ml on the 21st day. Rifampicin (1 μg/ml) showed slightly
increased activity than PA-824 at a lower concentration
of 3 μg/ml, with a reduction in the count of 1.42 log
cfu/ml on the 7th day, whereas for PA-824 at a concen-
tration of 12.5 μg/ml (P2), showed a decrease in the
count to log of 2.49 CFU/ml on the same day. A small
reduction in RIF activity was seen on the 7th day, and
on 14th day reduction of 2.34 CFU/ml was observed and
with no substantial change thereafter, whereas the activ-
ity of PA-824 at a concentration of 12.5 μg/ml continued
to show a steady activity and resulted in a 0 CFU/ml on
the 21st day. Since the experimentation was performed
in non-acid condition, the activity of PZA was not
efficient without any change in the log CFU/ml up to
21st day. Since PZA is not active in normal pH medium
as it needs acidic environment for its action, our findings
of low PZA activity in non-acidic pH fit with this
established fact (Table 1).Docking studies
The docking studies (Table 2) showed that Ligands 6
and 10 have the highest binding affinity of −8.4 and −8.0
Kcal/mol respectively with the wild type Ddn receptor
when compared to that of PA-824 which had a value
of −6.9 Kcal/mol. Considering the mutant receptor, the
binding of PA-824 was lowered to a value of −6.7 Kcal/
mol showing that the active site mutation has a potential
to lower the binding affinity. This trend was also
followed in Ligands 6 and 10 whose binding affinity
values were lowered to −8.1 and −7.7 Kcal/mol respect-
ively. Ligand 8, contradicted this trend showing an in-
crease from −7.7 Kcal/mol with the wild type receptor
to a value of −8.5 Kcal/mol with the mutant receptor.
Considering that ligand 8 has a higher affinity to the
wild type receptor itself than the PA-824, future evalua-
tions of this lead could be effected.
Table 2 Docking values of PA-824 and its novel analogues with the wild and mutant Ddn receptor
S.
no.
Drug Docking score with wild type
receptor (kcal/mol)
Docking score with A76E
mutant receptor (kcal/mol)
Structure of the analogues
1 PA-824 −6.9 −6.7






















Table 2 Docking values of PA-824 and its novel analogues with the wild and mutant Ddn receptor (Continued)
4 Ligand 3 (Hydroxyl
modification)
−6.3 −6.3
5 Ligand 4 (Biotin) −7.1 −6.7
6 Ligand 5 (Cholestryl
ester)
−8.3 −6.9



















Table 2 Docking values of PA-824 and its novel analogues with the wild and mutant Ddn receptor (Continued)
8 Ligand 7 (isoniazid) −7.8 −7.5
9 Ligand 8 (Moxi) −7.7 −8.5






















Figure 1 Bactericidal activity of PA-824 on Mycobacterium tuberculosis H37 RV under anaerobic condition. The treatment with 12.5 μg/ml
of PA-824 shows a complete reduction in the log CFU/ml after 21 days. P1 and P2: PA-824 at 3 and 12.5 μg/ml; R: Rifampicin at 1 μg/ml;
Z: Pyrazinamide at 50 μg/ml.
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Bactericidal activity
The main aim of people, who are working for the con-
trol of tuberculosis, is to have a shorter treatment regi-
men than shorten the current six months duration.
Following fluoroquinolones, few promising drugs were
developed including nitroimidazo-oxazine PA-824, de-
veloped by Global Alliance for tuberculosis and which is
in Phase II studies [7]. It has been shown that PA-824
has a novel mechanism of action affecting protein and
lipid synthesis of M. tuberculosis and has potential bac-
tericidal activity, which is comparable to that of isonia-
zid, a first line Anti-tuberculosis drug [8]. PA-824 also
appears to be active against non-replicating bacilli,
which suggests that it might be a potent sterilizing drug
[19]. Hence the in vitro study was undertaken with PA-
824, to understand its bactericidal activity on static and
anaerobic M. tuberculosis. After adaptation to micro
aerophilic culture, the organisms do not multiply and
the drugs that are capable of killing non-replicating bac-
teria are useful in treating latent infection with TB. This
helps to determine the sterilizing activity on M. tubercu-
losis in our experiments with single drugs This study
observed that the activity of PA-824 at the higher con-
centration of 12.5 μg/ml, was greater than standard
drugs such as RIF and PZA, which are known to have
significant sterilizing activity (Table 1 and Figure 1).
Lenaerts et al., [20] showed that with 10ug/ml, PA-824
treatment under anaerobic conditions a reduction of
0.99 CFU/ml, from 6.42 to 5.43 CFU/ml was observed at
the end of 28 days (24 days of anaerobic culture + 4 days
of drug treatment), compared to 6.42 CFU/ml in the
control. In our study, treatment with 12.5 μg/ml of PA-
824 showed a reduction to 4.69 ± 0.12 CFU/ml from6.58 ± 0.13 CFU/ml after 4 days of treatment, a net re-
duction of 1.89 CFU/ml which is higher than the reduc-
tion observed by Lenaerts et al., with 10 μg/ml. Further,
treatment with 2 μg/ml of PA-824 Lenaerts et al., [20]
showed a reduction of 0.81 CFU/ml from 6.42 to
5.61 CFU/ml compared to control. In this study with
3 μg/ml of PA-824, a similar reduction of persisting M.
tuberculosis count from 6.53 ± 0.07 to 4.93 ± 0.32 CFU/
ml (a reduction of 1.6 CFU/ml) in 21 days was observed.
This shows an approximate doubling of the killing activ-
ity (0.81 to 1.6 CFU/ml) when the concentration and
time are varied from 2 μg/ml (4 days) to 3 μg/ml
(21 days). An increase in the treatment concentration to
50 μg/ml of PA-824 for 4 days in the study by Lenaerts
et al., resulted in reductions to 5.24 CFU/ml whereas
the treatment of 12.5 μg/ml of PA-824 for 21 days,
which is a long term duration, resulted in complete re-
duction in the M. tuberculosis viable count. This could
signify an important role of concentration and duration
of PA-824 treatment that is required to control the
persisting M. tuberculosis.
Considering the role of PA-824 as a NO donor, excess
production of NO in the intracellular environment could
fuel the growth of M. tuberculosis through its ‘truncated
hemoglobin’ N (trHbN) detoxification machinery. In M.
tuberculosis H37Ra, the activity of the glbN gene encod-
ing trHbN is upregulated by the general nitrosative
stress inducer, nitrite, by the NO releaser sodium
nitroprusside and by hypoxia. The activity of the glbN
gene is also enhanced during M. tuberculosis H37Ra in-
vasion of THP-1 activated macrophages (producing NO)
[21]. In in vivo, the high oxygen affinity of trHbN (P50 ~
0.01 mm Hg) may ensure a low but critical level of
oxygen, granting survival of M. tuberculosis in the
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latency [22]. It has been proposed that the oxygenated
trHbN (oxy-trHbN) catalyzes the rapid oxidation of ni-
tric oxide to innocuous nitrate with a second-order rate
constant (k’NOD ≈ 745 × 10
6 m-1 · s-1), which is 15 and 34
fold faster than the reaction of horse heart and sperm
whale myoglobin, respectively [23,24]. The resulting
nitrate, the most effective alternate terminal electron
acceptor after molecular oxygen, could protect the M.
tuberculosis from hypoxic, acid and RNS stress [25].
From crystallographic studies, it is proposed that resi-
due Phe62 of trHbN exists in two conformations. In one,
the benzene side chain of the residue blocks the longer
channel of the tunnel path (the so-called closed state)
and in the other it does not (the open state) [26,27]. By
long Molecular dynamics (MD) simulations (0.1 ms),
Bidon-Chanal et al. have proposed that in deoxytrHbN,
the Phe62 adopts the closed conformation and hence the
O2 ligand enters the protein via the short channel. In
case of oxygenated trHbN, the Phe62 prefers the open
conformation, thus facilitating the entrance of the sec-
ond ligand (NO) via the long channel [28,29]. MD simu-
lations [30] have revealed two additional tunnels: EH
(EHT) and BE (BET). The conformational change from
an open state to a closed state is more rare than the op-
posite, indicating the presence of a larger energy barrier
for an open-to-closed transition. For the oxy-trHbN, the
open state conformer is found 1.5 kcal/mol more stableFigure 2 M. tuberculosis pathways associated with the dosage optimi
824 concentrations could favor M. tuberculosis antioxidant defense mechan
optimization of PA-824 therapy is a key parameter for successful killing of tthan the closed conformer. The energy barrier for closed
to open transition is ~1.2 kcal/mol whereas the reverse
energy barrier is >3 kcal/mol [31]. Adding to this, trHbN
matrix can hold more than one NO molecule at the
same time. Further •NO diffuses from the bulk solvent
through the channel to an internal cavity (EHc) of the
trHbN molecule. This cavity is located between the tun-
nel (EHT) entrance and the side chain of the Phe62 resi-
due. To reach EHc from the bulk, a NO must cross a
bottleneck region of 1.3 Å radius at the protein surface
[30]. This could be favored by the presence of diffusion
pressure under high NO concentrations generated by
treatment with excess PA-824. Further excess produc-
tion of NO in the intracellular environment could regu-
late autophagy, which is a host derived mechanism for
the endocytosis of M. tuberculosis and killing it by fusion
with lysosome [32,33]. Thus excess generation of NO it-
self could hinder the effectiveness of killing the bacteria.
This triggering of the detoxification machinery by NO
highlights the importance of dose and treatment dur-
ation optimization in PA-824 therapy which could other-
wise fuel the antioxidant survival strategies of M.
tuberculosis outlined in the above discussion (Figure 2).
This is also evident from the phase II clinical studies
wherein increasing the PA-824 doses resulted in an un-
changed Early bactericidal activity (EBA), with a steady
decrease in the number of TB bacteria in the sputum
(~0.1 log drop in CFU per day for 14 days, as comparedzation for PA-824 treatment. Excess NO release during elevated PA-
ism involving trHbN and down regulation of autophagy. Hence dose
he pathogen.
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maximum effectiveness was seen at the lowest dose
tested: 200 mg [7]. The 12.5 μg/ml concentration of
PA-824 and 21 days of treatment observed in this
study could enhance the clearance of M. tuberculosis
by overcoming its detoxification machinery. Thus the
optimum dosage and treatment duration could provide
better insights in setting the clinical evaluations using
free drug concentration greater than MIC (T>MIC) as a
parameter [34].
With respect to RIF, the findings of our study are simi-
lar to that of an in vivo model in mice, showing that PA-
824 was more active than RIF with more activity on the
metabolically active organisms but not on non-
replicating organisms [20]. Since the culture is in a pH
of 6.8, as expected the PZA activity was constrained
which has no bactericidal activity in non-acidic environ-
ments and the growth line in the graph (Figure 1) is
similar to that of no drug. PZA had more sterilizing ac-
tivity on slow multiplying organisms in an acidic condi-
tion inside macrophages [35], whereas PA-824 had more
sterilizing activity on non-replicating persisters.
Docking studies
Interaction of PA-824 with the active site of wild type re-
ceptor show two hydrogen bond interaction of the imid-
azole nitrogen (Position 7) with the two hydroxyl groups
of glutamic acid 83 represented in red (Figure 3). Inter-
action of PA-824 with the active site of mutant receptor
shows a total of two hydrogen bonds. The oxygen of
Nitro group interacts with Methionine 87 while the oxy-
gen atom at position 8 interacts with Tryptophan 88
(Figure 4). These interactions show that the key hydro-
gen bonding with Glutamic acid 83 present in the wildFigure 3 Interaction of PA-824 with the active site of wild type recep
the imidazole nitrogen (Position 7) with the two hydroxyl oxygens oftype receptor is absent in the mutant receptor. Ligand 8,
which showed a high affinity with the mutant receptor
showed a different scenario of binding with three hydro-
gen bond interactions (Figure 5). The carbonyl oxygen
showed interaction with Serine 78 (orange) and Lysine
79 (blue) and the oxazine oxygen showed interaction
with Methionine 87 (yellow). The Serine 78 residue in
the Ddn receptor is essential for the binding of F420, a
cofactor involved in Ddn activity, and PA-824 [16]. Thus
further investigation of the PA-824 binding in the
presence of F420 cofactor needs to be evaluated. Inter-
estingly, interaction of Ligand 8 with the wild type re-
ceptor showed no key hydrogen bond interactions. The
presence of hydrophobic and electrostatic interactions
could contribute to the better binding affinity value of
−7.7 kcal/mol (Figures 6 and 7).
Earlier in vitro and in vivo studies have shown an in-
creased activity of moxifloxacin-conjugated dansylated
carboxymethylglucan (M-DCMG) than free moxifloxacin
against persisting M. tuberculosis within macrophages
[36]. But this conjugation is not supportive for conjuga-
tion with PA-824 since Carboxymethylglucan has been
shown to have antioxidant activities [37] which could
counteract the essential ROS generation by PA-824 for
bactericidal activity. Interestingly, it is also pointed that
the efficacy of M-DCMG in improving the activity of
Moxifloxacin [36] was that its ability to localize with the
persisting tissues of C57BL/6 mice infected with M.
tuberculosis. Since PA-824 is known to localize to
persisting tissues [19], its conjugation with moxifloxacin
could provide a better therapeutic advantage against the
persistors. Wang et al., [38] noted that fuoroquinolones
such as moxifloxacin, appear to show enhanced action
in the presence of ROS. This support the enhancedtor show two hydrogen bond interaction (blue dotted lines) of
glutamic acid 83 (red) of the Ddn receptor.
Figure 4 Interaction of PA-824 with the active site of mutant receptor shows the two hydrogen bonds (blue dotted lines). The oxygen
of Nitro group interacts with Methionine 87 while the oxygen atom at position 8 interacts with Tryptophan 88.
Somasundaram et al. BMC Microbiology 2013, 13:218 Page 10 of 13
http://www.biomedcentral.com/1471-2180/13/218structure-activity relationship against M. tuberculosis
by ligand 8, which is a combinatorial structure of
moxifloxacin with an ROS/RNS generator - PA-824. The
support for the ester linkage for the structure activity of
the combinatorial drug design is provided by the work
by Georgopapadakou and Bertasso, [39], who showed
that cephalosporin 3′-quinolone ester (Ro 23–9424) is
effective in cases when neither of its individual compo-
nents, cephalosporin and quinolone, are active. In the
same way when there is resistance for moxifloxacin
and PA-824 as individual drugs, the ester combination
of both (ligand 8) could have a synergistic activity
against M. tuberculosis which could help in combin-
ation therapy. Further, since ligand 8 showed binding
at the hydrophobic pocket (red colour) of the Ddn re-
ceptor (Figure 6), it can be considered that the ligandFigure 5 Interaction of ligand 8 (Moxi) with the active site of mutant
lines). The carbonyl oxygen shows interaction with Serine 78 (orange) and
Methionine 87 (yellow).has more of hydrophobic interactions. This feature
could maintain the stability of the ester bond in the
presence of plasma and esterases as described by
Simões et al., [40]. A combination treatment of rifam-
pin, moxifloxacin, amikacin and PA-824 has shown
potent killing of MTB in vitro in 14 days [41]. Re-
cently, another study of phase II clinical trials in South
Africa, the combination therapy PaMZ, which consists
of the novel TB drug candidate PA-824, moxifloxacin
and pyrazinamide killed more than 99 per cent of peo-
ple’s TB bacteria within just 14 days and is potentially
suitable for treating both drug sensitive and multidrug
resistant tuberculosis [42]. Thus evaluation of treat-
ment strategies applying combinatorial/synergistic ac-
tivities could have a positive impact in the treatment
of TB.receptor shows three hydrogen bond interactions (blue dotted
Lysine 79 (blue) and the oxazine oxygen shows interaction with
Figure 6 Interaction of ligand 8 with the wild type receptor showed no key hydrogen bond interactions. While the hydrophobicity of
the binding pocket could contribute to the high binding affinity value of −7.7 kcal/mol.
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In summary PA-824 exhibited greater bactericidal activ-
ity on non-replicating organisms (persisters) under nor-
mal pH than that of RIF and PZA, which may help in
shortening the duration of treatment. Interestingly, the
dose of 12.5 μg/ml and 21 days treatment was observed
to have an ability to reduce the bacterial count to zero,Figure 7 Ligand 8 electrostatic interaction with the active site of wild
interaction which could account for its binding affinity value of −7.7which may offer key insights while setting the doses for
in vivo/clinical studies. From the combinatorial analysis,
ligand 8 (PA-824-Moxifloxacin ester conjugate) showed
the most potent activity against both wild type and mu-
tant Ddn receptors and hence needs further in vitro in-
vestigation of its enantiomeric binding properties with
the Ddn receptor.type receptor shows a favourable plateau of electrostatic
kcal/mol.
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